Date: 2017-05-08
Type of information: Pipeline acquisition
Compound: five consumer healthcare products including Prontalgine®
Company: Ipsen (France) Sanofi (France)
Therapeutic area:
Type agreement: pipeline acquisition
Action mechanism:
Disease:
Details:
- • On May 8, 2017, Ipsen announced that it has
completed its previously announced acquisition of a portfolio of five consumer healthcare products from Sanofi. The most significant product is Prontalgine®, an analgesic for the treatment of moderate to severe pain, only sold in France. The
portfolio also includes Buscopan®, an antispasmodic (sold in the Czech Republic, Estonia,Hungary, Latvia, Poland and Slovakia), Suppositoria Glycerini, a laxative (sold in the Czech
Republic), as well as Mucothiol® and Mucodyne®, expectorants for cough and flu, sold respectively in Greece and the Republic of Ireland. This transaction strengthens the evolution of Ipsen Consumer Healthcare portfolio in France and Central Europe with the strategic intent to further develop the OTx1 model in most geographies.
- • On February 13, 2017, Ipsen announced that it has entered into a definitive agreement to acquire from Sanofi
five consumer healthcare products in certain European territories. The most significant product is Prontalgine®, an analgesic for the treatment of moderate to severe pain, which has grown at double digit rates over the last four years and is available only in France. The portfolio also includes Buscopan® , an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol® and Mucodyne®, expectorants for cough and flu. Combined, these regional brands span a geographic scope of eight European countries. Manufacturing will be provided by third parties. David Meek, CEO of Ipsen, commented: “This tactical bolt-on transaction resulting from the European Commission’s requirement to divest certain assets from the Sanofi / Boehringer Ingelheim consumer healthcare deal strengthens our consumer healthcare portfolio in France with the addition of Prontalgine® . The opportunity immediately improves the profitability profile of Ipsen’s Primary Care business. It adds a limited portfolio of well-established and market leading brands in a key market such as France.”
Financial terms: Under the terms of the agreement, Ipsen will pay €83 million cash upon closing for the products. The transaction, which is subject to customary closing conditions, including the European Commission’s approval, is expected to close in the second quarter of 2017. The transaction will be fully financed by Ipsen’s existing cash and lines of credit.
Latest news:
Is general: Yes
